
Sierra Oncology SRRA
Quartalsbericht 2022-Q1
hinzugefügt 16.12.2023
Sierra Oncology P/S 2011-2026 | SRRA
P/S Jährlich Sierra Oncology
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| - | 558 | - | - | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 558 | 558 | 558 |
P/S anderer Aktien in der Pharmaeinzelhändler
| Name | P/S | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
1.75 | - | 2.43 % | $ 254 M | ||
|
BioNTech SE
BNTX
|
35.7 | $ 91.21 | 0.03 % | $ 27.2 B | ||
|
Alnylam Pharmaceuticals
ALNY
|
11 | $ 330.79 | 3.74 % | $ 43.3 B | ||
|
I-Mab
IMAB
|
94.1 | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
5.53 | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
1.96 K | - | 2.54 % | $ 160 B | ||
|
Cerus Corporation
CERS
|
2.12 | $ 1.87 | 0.27 % | $ 356 M | ||
|
CollPlant Biotechnologies Ltd.
CLGN
|
10.4 | $ 0.46 | -13.08 % | $ 5.27 M | ||
|
Midatech Pharma plc
MTP
|
137 | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.39 K | - | -1.52 % | $ 24.7 M | ||
|
Acorda Therapeutics
ACOR
|
0.142 | - | -24.86 % | $ 820 K | ||
|
Adverum Biotechnologies
ADVM
|
76.4 | - | - | $ 86.2 M | ||
|
Advaxis
ADXS
|
144 | - | -9.65 % | $ 45.9 M | ||
|
Aeterna Zentaris
AEZS
|
7.87 | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
0.099 | - | -10.17 % | $ 12.2 K | ||
|
AIkido Pharma
AIKI
|
0.935 | - | 1.93 % | $ 17.4 M | ||
|
Aeglea BioTherapeutics
AGLE
|
489 | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
65.5 | - | - | $ 26.5 M | ||
|
Институт стволовых клеток человека
ISKJ
|
2.61 | - | - | - | ||
|
Catalyst Pharmaceuticals
CPRX
|
5.16 | $ 24.91 | 0.89 % | $ 3.05 B | ||
|
Corbus Pharmaceuticals Holdings
CRBP
|
2.86 | $ 10.08 | -0.88 % | $ 134 M | ||
|
Cardiff Oncology
CRDF
|
196 | $ 1.59 | 0.32 % | $ 106 M | ||
|
Alpine Immune Sciences
ALPN
|
8.94 | - | - | $ 2.17 B | ||
|
Curis
CRIS
|
1 | $ 0.53 | -3.58 % | $ 6.98 M | ||
|
Aquestive Therapeutics
AQST
|
10.5 | $ 4.1 | -0.85 % | $ 438 M | ||
|
Crinetics Pharmaceuticals
CRNX
|
534 | $ 37.76 | 1.42 % | $ 3.55 B | ||
|
CRISPR Therapeutics AG
CRSP
|
1.25 K | $ 49.35 | -0.32 % | $ 4.44 B | ||
|
CytomX Therapeutics
CTMX
|
12.2 | $ 4.35 | -4.61 % | $ 600 M | ||
|
Citius Pharmaceuticals
CTXR
|
1.21 K | $ 0.88 | 2.44 % | $ 5.92 M | ||
|
Cue Biopharma
CUE
|
1.07 | $ 0.17 | -6.06 % | $ 16.1 M | ||
|
Aravive
ARAV
|
6.61 | - | -13.39 % | $ 1.45 M | ||
|
Arcturus Therapeutics Holdings
ARCT
|
2.65 | $ 8.24 | 2.55 % | $ 226 M | ||
|
Cyclerion Therapeutics
CYCN
|
3.27 | $ 4.13 | -32.85 % | $ 10.4 M | ||
|
Aptinyx
APTX
|
204 | - | -39.0 % | $ 4.57 M | ||
|
Daré Bioscience
DARE
|
16.4 | $ 1.77 | 1.75 % | $ 19.8 M | ||
|
DBV Technologies S.A.
DBVT
|
500 | $ 20.47 | -2.8 % | $ 2.86 B | ||
|
CureVac N.V.
CVAC
|
281 | - | - | $ 867 M | ||
|
AstraZeneca PLC
AZN
|
2.17 | - | - | $ 96.9 B | ||
|
Celldex Therapeutics
CLDX
|
1.32 K | $ 31.46 | 1.29 % | $ 2.09 B |